Polfa wins acceptance for bold new development plan

The investment was earlier blocked by the Polfa's main shareholder, Polish Pharmaceutical Holding (PHF). It was not sure whether the new medicines would be registered by the relevant authorities. "In line with state regulations, we submitted samples to the Public Health Institute for testing. We hope that preparatory works for the new investment will start at the beginning of 2006," stated Mirosław Mazurek, the head of the office of Polfa Warszawa board. Polfa prepared three products in cooperation with domestic partners and intends to produce another six medicines under licenses. Production is to be launched in Q4 2007 and the products will enter the market in 2008. Polfa's board refused to reveal what revenues and profits it expects from the investment, but the new medicines are to compete with the products of foreign pharmaceutical concerns such as BMS, Ivax or Aventis. (Puls Biznesu, pp. 1, 8) E.B.